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The specific treatment of hypertension in preg-
nancy is still a matter of dispute. In the United
Kingdom, some obstetricians never use anti-
hypertensive treatment in the management of even
severe preeclampsia [1]. Instead, emphasis is given
to the use of anticonvulsants such as diazepam or
chlormethiazole. In the United States, parenteral
magnesium sulphate, which has no hypotensive ac-
tion, is the first line of treatment [2].
Treatment of extreme hypertension in pregnancy
Rationale for treatment. There is considerable
evidence to demonstrate the deleterious effects of
sudden increments in blood pressure (above a criti-
cal value) in nongravid humans and experimental
animals. In rats, acute increases to values above a
mean pressure of 150 mm Hg rapidly cause focal
arteriolar damage [3]. Experimentally, this is well
seen in the mesenteric arterioles of the rat, which
develop alternating constrictions and dilatations,
resembling a string of beads [4]. The damaged areas
are confined to the dilated segments, where there
are endothelial tears that allow plasma to track into
and disrupt the media [5]. At these points, the arte-
rioles are both abnormally permeable and unable to
maintain their normal tone. The critical feature is
the speed with which hypertensive damage evolves:
histologic abnormalities are detectable within 10
mm and have become extensive after 1 hour [3].
The malignant phase of hypertension may be
solely explicable by this sequence of hypertensive
arteriolar injury [6], although it has been claimed
that the augmenting action of humoral factors, such
as antidiuretic hormone, is also necessary [7].
The functional effect of pressure-forced dilatation
of arterioles is a loss of autoregulatory control with
exposure of more peripheral vessels to high-pres-
sure hyperperfusion. Experimentally and clinically,
this has been demonstrated in the brain [8] and is
the cause of hypertensive encephalopathy and reti-
nopathy [9]. The threshold for forced dilatation is
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probably lower in previously normotensive than it
is for chronically hypertensive individuals in whom
the arterioles have adapted structurally to higher
pressures [8].
The same processes extending over longer peri-
ods of time are thought to cause cerebral micro-
aneurysms, which in turn can rupture to cause cere-
bral hemorrhage. Thus, it is possible to explain why
high blood pressure causes cerebral hemorrhage,
why very high blood pressure causes acute cerebral
dysfunction, and why both problems are prevented
by adequate hypotensive treatment.
In pregnancy, previously normotensive women
may rapidly develop extreme hypertension to levels
where all the clinical and experimental evidence
would suggest that arterial and arteriolar damage
should acutely ensue. Nevertheless, eclampsia is
not simply a variant of malignant hypertension. The
two conditions are similar in that they can include
convulsions, death from cerebral hemorrhage, heart
failure, hypovolemia, proteinuria, progressive ure-
mia, disseminated intravascular coagulation, and
microangiopathic hemolysis [10, 1.1]. But there are
differences. In eclampsia, cerebral edema is not a
notable autopsy feature [12]. The liver is peculiarly
a target organ for the preeclamptic process, show-
ing periportal hemorrhages and infarcts [12].
The arterial intimal proliferation of malignant hy-
pertension [13] is not a feature of preeclampsia [14],
although it is seen in the separate syndrome of post-
partum renal failure [15]. This difference may be
simply a function of the brevity of most eclamptic
illnesses in that intimal proliferation is a secondary
response taking time to develop after primary arte-
rial injury [16]. The retinal fundal changes of malig-
nant hypertension are usually not seen in eclamp-
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sia. Careful examination of the retinal arterioles will
nevertheless reveal the alternating segments of con-
striction and dilatation that are characteristic of hy-
pertensive injury [3, 17].
Therefore, even if eclampsia is not malignant hy-
pertension, there is considerable evidence that it is
a form of hypertensive encephalopathy. The only
other explanation for the convulsions is that they
result from ischemic injury caused by micro-
vascular thrombosis [18]. This would categorize
eclampsia nearer to thrombotic thrombocytopenic
purpura, with which it may be confused diagnosti-
cally [19].
An increasing proportion of women who suc-
cumb to eclampsia die of cerebral hemorrhage
(Table 1). At autopsy, there are petechiae in the
cortex, white matter, and midbrain, associated with
capillary thrombi. Larger hemorrhages, which may
rupture into the subarachnoid space, are found in
the white matter, basal ganglia, and pons [12]. They
are similar to those seen in older hypertensive indi-
viduals and are associated with arterial wall necro-
sis [20].
The autopsy evidence is consistent with hyper-
tensive cerebrovascular injury as the prime causes
of eclampsia. Claims that hypertension is not al-
ways a feature of eclampsia may result from prob-
lems of blood pressure measurement [21] or from a
failure to recognize that hypertensive injury may
precede rather than coincide with eclamptic con-
vulsions. Although activation of the clotting system
is not simply secondary to vascular injury, in that it
can be detected before extreme hypertension has
developed [22], it is also possible to have eclampsia
without coagulation abnormalities [23]. This argues
Table 1. Maternal deaths in England and Walesa
Due to eclampsia
and cerebral
All Due to hemorrhage
maternal eclampsia % of all
deaths % of all deaths eclamptic deaths
1961-63 692 40
(5.8%)
13
(32.5%)
1964—66 579 40
(6.9%)
14
(36.0%)
1967-69 455 41
(9.0%)
10
(24.4%)
1970—72 355 29
(8.2%)
16
(55.2%)
1973—75 235 21
(8.9%)
11
(52.4%)
a Data from Reports on Confidential Enquiries into Maternal
Deaths in England and Wales. London, HMSO, 1966, 1969,
1972, 1975, 1979
against a thrombotic etiology for eclampsia. It must
therefore be concluded that unless pregnant women
have arterial systems totally unlike nonpregnant in-
dividuals and experimental animals, the sudden in-
creases of blood pressure characteristic of pre-
eclampsialeclampsia are the most likely cause of the
neurologic features and the cerebral pathology.
Principles of treatment of extreme hypertension
in pregnancy. Blood pressures of 170 to 180/1 10 to
120 represent mean arterial pressures of 130 to 140
mm Hg. These are close to the limits where experi-
mental hypertensive vascular damage begins. Thus,
on general principle, blood pressures at or above
170/110 should be treated. The decision to treat is
based on the maximum blood pressures recorded
in any period.
The diagnosis of extreme hypertension in preg-
nancy is nearly always preeclampsia, which may be
superimposed on chronic vascular or renal disease.
In general, the basic management of preeclampsia
hinges around two issues: detection (by screening
the asymptomatic patient) and timely delivery. The
former demands that antenatal care facilities be pro-
vided and used; the latter guarantees a cure for all
preeclamptic hypertension and is, where possible,
preferable to any system of medical treatment.
The possible methods of management have been
recently reviewed by several authors [24—3 1].
Arteriolar constriction, of unknown origin,
causes preeclamptic hypertension. It is probably
not mediated through the sympathetic nervous sys-
tem. Whether or not angiotensin is involved is dis-
puted (reviewed in Ref. 11). Despite fluid retention,
there is plasma volume depletion and reduced renal
and placental perfusion [11].
The vasospasm responds best to the drugs that
directly relax vascular smooth muscle, namely
diazoxide and hydralazine. These are the agents of
choice for acute hypertensive emergencies in preg-
nancy. Both are usually used in the immediate pen-
partum period. Neither has been tested in adequate-
ly controlled trials.
Hydralazine has probably been used more exten-
sively in pregnancy than has diazoxide [32-34]. It is
best reserved for transient rises in blood pressure,
which are treated with intermittent i.m. or s.c.
administration of 10 to 20 mg. Side effects are
more likely to be troublesome with continuous
i.v. infusion, and because they comprise head-
aches, vomiting, shakiness, and even hyperreflexia,
they can mimic impending eclampsia. Hydralazine
has a weak and transient action. Its effectiveness is
enhanced by concurrent sympathetic inhibition,
Treatment of hypertension in pregnancy 269
which blocks the reflex tachycardia that develops as
the blood pressure falls. In pregnancy, this is
achieved if the patient is already on methyldopa.
Fetal side effects have not been reported. Some of
the hydralazine metabolites are, however, poten-
tially very toxic, and therefore it should not be used
indiscriminately or at levels exceeding 300 mg in 24
hours.
Diazoxide has mainly been used for intrapartum
hypertensive emergencies [35—38]. Its ability to re-
duce the blood pressure within minutes has been
amply confirmed. The standard dose of 300 mg by
rapid i.v. injection is excessive and can cause seri-
ous hypotension [38]. The tendency to hypotension
is probably aggravated by the plasma volume deple-
tion of preeclampsia and is more likely if the patient
is already on sympathetic blocking drugs. Titration
by intermittent administration of small boluses of 30
to 60 mg is preferable and effective [24, 39]. Diazox-
ide relaxes uterine muscle and usually inhibits labor
[40, 41]. The advantages of using diazoxide have re-
cently been queried [42]. There is no doubt that it is
a drug to be reserved for the most extreme situa-
tions (in our practice less than 0.05% of all mater-
nities). Apart from hypotension and shock, neo-
natal hyperglycemia after acute administration in la-
bor has been reported [38]. The same is seen in
utero in fetal lambs from sheep given 15 mg/kg/day
of i.v. diazoxide for 100 hours (more than should be
used clinically). After delivery, fetal pancreatic beta
cell destruction was seen, as well as cataracts and
muscle abnormalities in one animal [43]. On the oth-
er hand, diazoxide is the most likely drug to suc-
cessfully control dangerous hypertension, and if
used cautiously, is probably the safest option in
these circumstances.
If the renin-angiotensin system causes the hyper-
tension of preeclampsia, then agents that inhibit its
action might, in the future, be a useful part of treat-
ment. In the immediate postpartum period, a con-
verting enzyme inhibitor (SQ 20,881) did not lower
the blood pressure of five preeclamptic women [44].
Experimentally, the angiotensin antagonist sarala-
sin reduces the blood pressure of the pregnant ewe
in a dose-dependent fashion [45]. Clinical studies of
its use have not been reported.
Lowering the blood pressure and placental per-
fusion. How perfusion of the human placenta is
controlled is poorly understood because of the obvi-
ous ethical problems of measurement and experi-
mentation. Moreover, animal observations are fre-
quently limited to measurement of uterine artery
flow, which may not reflect placental flow. The
healthy human placenta must have a capacity to
function normally over a range of different maternal
blood pressures, including the 15% drop in mean ar-
terial pressure that occurs at night during sleep [46].
But in preeclampsia, placental blood flow is re-
duced [11] because of gross obstructive changes in
the spiral arteries [47], which in themselves could
limit the effectiveness of any mechanism of autoreg-
ulation of blood flow.
Whether or not acute hypotensive treatment
causes reduced placental perfusion cannot be an-
swered directly. Neither do clinical studies of fetal
morbidity or mortality after treatment provide use-
ful information, because there are no controlled ob-
servations. It is general experience, however, that
therapeutic reduction of maternal pressure does not
cause apparent fetal problems and may be compati-
ble with a continuing intrauterine existence over pe-
riods of weeks. Controlled clinical studies have
demonstrated that long-term hypotensive treatment
does not retard fetal growth despite significant
blood pressure reduction [48, 49].
In some vascular beds, blood flow increases after
hypotensive treatment, demonstrated in the pre-
eclamptic myometrium after i.v. hydralazine [50].
Likewise in the pregnant ewe, with renal artery clip
hypertension, hydralazine increases uterine artery
flow—a change mediated by the reflex sympathetic
increase in cardiac output [51]. Diazoxide in the hy-
pertensive or normotensive ewe reduces uterine
perfusion [51-53]. The increased uterine flow in
pregnant monkeys after angiotensin II infusion is
abolished by pretreatment with indomethacin,
whereas the hypertensive response is augmented
[54]. Here, prostaglandins are apparently the de-
terminants of changes in uterine flow, not the arteri-
al pressure. Autoregulation of rabbit placental
blood flow has been claimed [55], with a lower limit
of arterial pressure below which flow diminishes.
Presumably this threshold explains the reduced pla-
cental flow after bethanidine-induced hypotension
in rabbits, which has also been reported [56].
Whether or not these observations are relevant to
the management of preeclamptic hypertension is ar-
guable. If perfusion of a preeclamptic placenta can
only be maintained by a blood pressure that directly
threatens maternal well-being, then urgent delivery
is the main priority. In practice this must, in my ex-
perience, be a rare circumstance.
Conservative treatment of moderate and severe
preeclampsia. The earlier the presentation, the
more justified it is to attempt conservative manage-
ment of preeclampsia in order to allow fetal matura-
270 Redman
tion and enhanced neonatal survival. The patient
must be asymptomatic, have adequate renal func-
tion, and be under constant in-patient supervision.
In these circumstances, parenteral therapy is in-
appropriate, and oral agents need to be used.
Methyl dopa is the first choice.
The safety of methyl dopa in pregnancy has been
established by uncontrolled and controlled studies
[48, 57—59]. No serious adverse fetal effects have
yet been documented. its use not only relieves the
patient of the problems of parenteral therapy, but if,
at a later time, diazoxide or hydralazine is needed,
their action is potentiated because the sympathetic
reflex tachycardia, which these agents induce, is in-
hibited.
Although methyl dopa can be given i.v., oral ad-
ministration can achieve an adequate therapeutic
response within 12 hours provided a large initial
loading dose of 750 to 1000mg is used (Fig. 1). This
can be followed by 1.0 to 2.0 g!day, which is rapidly
adjusted to 3.0 to 4.0 g/day as needed. A satisfac-
tory drop in the blood pressure tends to provoke
transient oliguria, which may cause anxiety about
preeclamptic renal failure —a complication easily
discounted by measuring the plasma urea and
creatinine. Despite good blood pressure control, the
other changes of preeclampsia (abnormalities of
renal, coagulation, and placental function) remain
unchanged. Thus, hypotensive treatment is merely
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Fig. 2. Two 24-hour blood pressure records on the same patient,
the first at 24 weeks and the second at 34 weeks when she had
proteinuric preeclampsia treated with oral methyl dopa. The re-
versal of the normal circadian pattern of blood pressure is
shown. (See Ref. 46)
suppressing one dangerous manifestation of the dis-
order.
Nocturnal hypertension preeclampsia. The blood
pressure normally falls during sleep, both in preg-
nant and nonpregnant subjects. In preeclampsia,
the nocturnal fall is at first lost [60], and later the
circadian pattern is reversed with the appearance of
nocturnal hypertension [46] (Fig. 2). Any treatment
regimen of hypertension in preeclampsia may need
to anticipate nocturnal hypertension by a variable
schedule, with the largest doses at night.
Escape from blood pressure control. While preg-
nancy continues, preeclampsia is a relentlessly pro-
gressive disorder, so that sooner or later escape
from blood pressure control can be expected. In
general, the maternal and fetal condition deteriorate
together, and it is not difficult to see when the limits
of conservative management have been reached
and delivery is indicated. Oral vasodilators, how-
ever, may be usefully added to the medical regime
to prevent loss of blood pressure control. Oral hy-
dralazine, which on its own is a weak hypotensive
Methyl dopa dose (by mouth)
750mg 500mg 750mg 750mg 750mgII I I 34 weeks—o Methyl dopa,750mg24 weeks
No treatment
15.00 18.00
8-00
0.0o0
22.00 02.00 .00
Time, hours
Fig. 1. Control of preeclamptic hypertension using oral methyl
dopa only. The patient was transferred from another unit at 28
weeks in her second pregnancy with progressive hypertension
and proteinuria. Her first pregnancy ended at 28 weeks with
eclampsia, placental abruption, intrauterine death, and acute
renal failure. With conservative management, this pregnancy
continued until delivery at 30 weeks of a healthy son weighing
1020 g.
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agent, effectively augments methyl dopa given at
doses of 25 to 75 mg every 6 hours.
The long-term use of oral diazoxide has been
tried in four pregnancies for 19 to 69 days [61]. Two
of the patients were diabetic, of whom one could
have been suffering from diabetic nephropathy,
rather than preeclampsia. Diazozide was detected
in cord blood and amniotic fluid and excreted in the
neonates' urine for the first week of life. No effect
of diazoxide was discernible on the neonatal blood
pressure or blood sugar levels, although the two off-
spring of diabetic mothers had abnormal glucose
tolerance at 24 hours of age. All the babies devel-
oped some degree of alopecia; and one, hyper-
trichosis lanuginosa. In other respects, the neonates
developed normally except that one had a retarded
bone-age at 1 year [62]. In Oxford, we have used
oral diazoxide in four pregnant patients, of whom
three had severe preeclampsia. One of the three in-
fants survived and is normal at the age of 1 year.
The fourth patient had disseminated lupus erythe-
matosus with milder superimposed preeclampsia.
Treatment with methyl dopa and diazoxide was
started at 202 and 206 days' gestation, respectively.
Delivery was at 253 days, of a live male weighing
2090 g, who developed transient hyperglycemia in
the neonatal period (Fig. 3).
Other measures that have been used. Hyporo-
lemia is a well-documented feature of preeclampsia
[11, 63], and it has been claimed [64], and disputed
[65], that plasma volume expansion is beneficial.
Other workers have tried hemodialysis [66], hepa-
rinization [67], or plasmapheresis [68], with varying
claims of success. Diuretics are frequently used,
but with what objectives (given the plasma volume
depletion of most preeclamptic women) is not clear.
All the reports are uncontrolled and, therefore, of
limited value.
Treatment of mild to moderate hypertension in pregnancy
Rationale for treatment. In medical practice, the
objectives of treating moderate hypertension span a
decade or more of the middle and later parts of an
individual's life, and the success of treatment is
measured by the prevention of heart failure,
aortic dissection, coronary vascular disease, and
stroke. The same aims are not necessarily trans-
ferable to young women for the brief period of
pregnancy; nor do nonobstetric studies provide any
guidelines as to how treating moderate hyperten-
sion might affect the fetus.
In general, moderate hypertension in pregnancy
(140 to 170/90 to 110) has three inherent risks: it pre-
cipitates complications of other maternal disorders;
it is the precursor of more severe (preeclamptic) hy-
pertension; and it implies decreased perinatal sur-
vival.
Aortic dissection occurs more commonly in preg-
nancy [69], particularly in association with hyper-
tension [70]. It is thought that hypertension inter-
acts with an underlying abnormality, such as with
Marfan's syndrome [71], but that pregnancy itself
does not cause predisposing intrinsic aortic changes
[72]. Pedowitz reported a maternal mortality of 93%
[70]. Myocardial infarction complicates about
0.01% of maternities, occurring particularly and not
surprisingly in older women [73]. It may be associ-
ated with hypertension, especially in the 3rd trimes-
ter [74]. The lesion is not always coronary artery
thrombosis; periarteritis and dissecting hematomas
of the coronary arteries have been documented [75-
77]. In pregnancy, hypertension increases the risk
of bleeding from cerebral aneurysm but not cerebral
angioma [78]. Pregnancy itself predisposes to carot-
id artery occlusion superimposed on atheromatous
disease, but hypertension does not seem to be a
relevant factor [79]. These are all very rare compli-
cations and cannot in themselves justify the treat-
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Fig. 3. Infant delivered at 36 weeks' gestation to a mother with
moderate preeclampsia superimposed on severe hypertension
complicated by disseminated lupus erythematosus. For the last
47 days of pregnancy, oral diazoxide (150 mg daily) had been
given. Transient hyperglycaemia treated by i.v. insulin was the
only neonatal complication.
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ment of all cases of moderate hypertension in preg-
nancy.
The risks in pregnancy of a moderately elevated
blood pressure in terms of later severe hypertension
or perinatal death are closely linked and related to
the further question of how chronic hypertension
predisposes to preeclampsia. The likelihood of de-
veloping proteinuric preeclampsia increases two-
fold to sevenfold if there is preexisting maternal hy-
pertension [80-841. Consequently, at every stage of
gestation, a raised blood pressure augments the risk
of later more severe hypertension or of perinatal
death, either directly or indirectly. Most of the spe-
cific obstetric risks of chronic hypertension appear
to be mediated through superimposed preeclamp-
sia: without this complication, pregnancies with
chronic hypertension have a similar or even better
perinatal mortality than do normal pregnancies
[85]. These associations do not demonstrate that
the hypertension causes the problems. That hy-
potensive treatment may not prevent them is an
obvious corollary.
In preeclampsia, the uterine spiral arterioles are
blocked by accumulations of lipophages, fibrin, and
platelet aggregates —so-called acute atherosis"
[86]. These lesions account for the reduced uter-
oplacental blood flow of preeclampsia, as well as
the increased incidence of placental infarcts [87],
and the placental dysfunction that causes intra-
uterine asphyxia or growth retardation. Despite
claims to the contrary [88], there is evidence that
these are not exclusive to hypertensive pregnancies
[89]. In particular, placental infarcts are relatively
common in normotensive pregnancies [87], and pre-
sumably share the same vascular pathology. There-
fore, it is unlikely that they are caused or ex-
acerbated by high blood pressure, but possibly have
an immune etiology [90]. There is a parallel, in that
the vascular lesions of renal allograft rejection were
originally ascribed to hypertension before their im-
mune basis was established.
Therefore, neither on maternal or fetal grounds is
there compelling background evidence that mild to
moderate maternal hypertension should be treated.
Evidence from clinical studies. After it had been
shown that the treatment of severe hypertension in
pregnancy with methyl dopa was compatible with a
successful outcome [57, 58], the first controlled trial
of its use for mild hypertension in pregnancy was
reported [59]. One hundred women (diastolic blood
pressure  90 mm Hg) were randomly allocated to
no treatment, or methyl dopa combined with a diu-
retic. In women who were normotensive before the
20th week and later became hypertensive, treat-
ment seemed to confer no benefit. But in those
whose hypertension antedated the 20th week, ac-
tive treatment was associated with a significantly
-better fetal outcome with no losses in the treated
group and five losses, including three midtrimester
abortions, in the control group (Table 2).
Comparable results were reported in a similar but
larger controlled trial of treatment with methyl dopa
[48, 49] in which diuretics were not used. Patients
with severe hypertension were excluded because
hypotensive treatment could not be ethically with-
held. A specific purpose of this trial was to inquire if
early control of long-standing maternal hyper-
tension prevented later superimposition of pre-
eclampsia. The diagnosis of preeclampsia had to be
made using new criteria because the use of hypoten-
sive drugs nullified the usual definitions based on
blood pressure levels. Proteinuria occurred so infre-
quently as not to be a useful indicator. Therefore,
changes in plasma urate were used. A rising plasma
urate is an early feature of preeclampsia [91] and is
caused by a reduced renal urate clearance occurring
independently of changes in the GFR (reviewed in
Ref. 11). It correlates well with the renal biopsy
changes of the disorder [14] and is associated with
an increased perinatal mortality [92], Serial mea-
surements of plasma urate clearly demonstrated no
differences between the two groups (Table 3).
This confirmed the analysis of fetal outcome: al-
though it was significantly better with active treat-
ment, the benefit could not be attributed to pre-
vention or control of hypertensive complications.
In particular, as in the earlier trial, midtrimester
abortions were confined to the control group, and
none of them were apparently directly caused by
maternal hypertensive disease. The improved pen-
natal outcome therefore remains unexplained but
could be a consequence of some other action of
methyl dopa. The obvious hypothesis is that it is
Table 2. Perinatal outcome in two controlled trials of
antihypertensive treatment in pregnancy
Total Midpregnancy Perinatal
patients abortions deaths
Leather eta! (1968) [591
Control 48 3 6
Treata 52 0 6
Redman eta! (1976) [48]
Control 125 4 5
Treath 117 0 1
a Methyl dopa and bendrofluazide
Methyl dopa and other hypotensive agents if needed, but no
diuretics
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Table 3. Incidence of superimposed preeclampsia in trial of
methyl dopa for chronic hypertension in pregnancy.a
Rise in uric acid
Control(N = 103)
Treat
(N = 101)
None, no. of patients 44 (42.7%) 39(38.6%)
Moderate, no. of patients 57(55.3%) 59(58.4%)
Mean time of rise, days 241 25 240 24
Severe,no. of patients 2(1.9%) 3 (3.0%)
Mean time of rise, days 208 232
a A moderate rise in plasma urate was defined as increases of
30 to 120 iM at each of three successive followups. A severe rise
in plasma urate was defined as an increase of more than 120 /SM
between two successive followups. See Refs. 48 and 49.
affecting myometrial activity. This is supported by
the observation that treated women labored less ef-
fectively. There were more emergency Cesarean
sections for failure to progress, which was statisti-
cally significant for those women who had a com-
bined medical and surgical induction [24].
The other main benefit of treatment was the re-
duction, but not abolition, of severe hypertensive
episodes [49]. Blood pressure control and side ef-
fects with methyl dopa, using 0.75 to 4.0 g!day,
were as would be predicted from medical experi-
ence. Methyl dopa could not be tolerated by 14.5%
of women, and they were transferred to debris-
oquine, clonidine, or bethanidine. Oral hydralazine
was the most commonly used agent to augment the
action of methyl dopa, but was never used on its
own.
The birth weights of the surviving babies were
similar. The conclusion that hypotensive treatment
had not altered fetal growth was confirmed by mul-
tivariate analysis and is consistent with similar in-
cidence of superimposed preeclampsia in the two
groups.
The condition of the neonates at birth, the need
for resuscitation, neonatal complications, and prog-
ress is the first year of life were also all similar in
the two groups [93, 94].
The average head circumference of the treated
neonates, however, was reduced by a small but sig-
nificant amount: treated, 34.2 1.7 cm; untreated,
34.6 1.3 cm (averages 1 SD). This difference
was not associated with the total amount of methyl
dopa prescribed, the duration of treatment, or the
average daily doses. But the neonates involved
were born to those mothers who started treatment
between 16 and 20 weeks' gestation [95]. This is a
period when intrauterine brain growth is particular-
ly rapid, so that it is possible that the onset of treat-
ment at this time affected head growth. The follow-
up of these children, however, has been completely
reassuring in terms of overall growth and develop-
ment. The subset of treated babies with smaller
head circumferences have developed normally and
do not differ either from the rest of the treated group
or the control infants. Furthermore, average age-
standardized scores of developmental attainment
with respect to gross motor, fine motor, visuomotor
functions, language, and comprehension have been
systematically better in all categories, in girls and
boys separately, in treated compared with un-
treated children [96]. This assessment was done at
the age of 4 years and is being repeated with the 7
year olds. This is a unique long-term pediatric fol-
lowup of a controlled trial of hypotensive treatment
in pregnancy. It therefore is the only information
available concerning possible long-term adverse fe-
tal effects of treatment. The use of methyl dopa
seems to be free of frequent or major problems, ex-
cept that treatment should not be started between
16 and 20 weeks' gestation to avoid possible effects
on fetal head growth.
A recent small controlled trial using a diuretic
combined with methyl dopa or hydralazine for
chronic hypertension in multiparas claimed that
treatment prevented "pregnancy-aggravated" hy-
pertension [97]. It is not clear if this means pre-
vention of superimposed preeclampsia or merely
that the hypotensive treatment exerted its intended
effect. The perinatal outcomes were similar in the
two groups.
Other measures for the prevention of pre-
eclampsia. Diet, salt restriction, bedrest, and non-
specific sedation have all had their advocates. For
severe recurrent preeclampsia, long-term anti-
coagulation has been tried [98]. But diuretics re-
main the most extensively investigated.
Diuretics. All the adequately controlled trials
agree with each other that neither perinatal mortali-
ty nor the incidence of proteinuric preeclampsia is
modified by the prophylactic use of diuretics [99-
104]. Where this benefit has been claimed, edema
has been included as a diagnostic sign of pre-
eclampsia, and the outcome merely reflects the ca-
pacity of the diuretics to clear edema [105, 106]. In
one other study, a massive improvement in pen-
natal mortality was associated with diuretic therapy
[107]. But the treatment group was heavily biased
by a composition in favor of the better perinatal
mortality that was observed. Two high-risk groups
were selectively removed from the treated category
only—that is, women with asymptomatic bacte-
riuria and treatment defaulters. The latter were
transferred to the control group for analyzing the
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results which, because they do not represent the
outcome of true randomisation, need to be dis-
counted.
There is no evidence that diuretics are beneficial
for the treatment of established preeclampsia ei-
ther, although their use is still strongly advocated
[30, 108]. They will aggravate the hypovolemia of
the disorder and in these circumstances can precipi-
tate iatrogenic renal failure [109]. The fetal con-
sequences of the diabetogenic effects of thiazide
compounds are not defined. Diuretics have caused
maternal deaths from pancreatitis [110], electrolyte
disturbances [11 1], and excessive ingestion [112].
They cause hyperuricemia, which obscures what is
one of the most useful signs of early preeclampsia.
Neonatal thrombocytopenia and hemolysis associ-
ated with their antenatal use have been documented
[113, 114].
It cannot be concluded that there is an absolute
contraindication to diuretics in pregnancy. But giv-
en their many disadvantages and the absence of
clear evidence in favor of their use, there seem to be
good reasons for avoiding them. The only exception
is for the treatment of left ventricular failure, a rare
complication of severe preeclampsia.
Beta-adrenoceptor blocking agents. These drugs
have been used in pregnancy for the treatment of
hypertension [115—122], cardiac dysrythmias [123—
127], thyrotoxic symptoms [118, 123, 128, 129], and
hypertrophic obstructive cardiomyopathy [130-
133]. At present their safety in terms of adverse re-
actions of the fetus is not established. The available
information is confusing, because it chiefly com-
prises uncontrolled case reports or series, in which
it is impossible to separate fetal problems ascribable
to treatment from those ascribable to the condition
for which the treatment is given. Intrauterine
growth retardation, respiratory difficulties at birth,
neonatal bradycardia, and hypoglycemia have all
been reported as possible problems after long-term
propranolol at levels of 20 to 240 mg/day [116, 118,
121, 123—125, 131]. The largest series (uncontrolled)
is of 101 mothers treated for hypertension with me-
troprolol in various combinations with hydralazine
or diuretics [122], with a perinatal mortality of 1.9%
and with 11.7% of the infants "small for dates" to
an undefined extent. Neonatal hypoglycemia or
bradycardia were not noted. This lack of complica-
tions agrees with one other smaller but similar se-
ries [117], but not with that of Lieberman eta! [120]
who identified propranolol as a factor possibly con-
tributing to fetal demise in 9 patients with severe
hypertension and renal disease.
There are only two controlled studies. A small
randomized trial of i.v. propranolol to prevent acute
hypertension during induction of anesthesia for
Caesarean section clearly implicated propranolol as
a cause of neonatal respiratory depression [134]. In
the second study a significantly improved fetal out-
come was observed in 26 hypertensive patients
treated with long-term oxprenolol compared with 27
patients treated with methyl dopa [115]. The inves-
tigators claimed that oxprenolol not only controlled
maternal hypertension but promoted plasma vol-
ume expansion causing the apparently better fetal
growth in the oxprenolol-treated group. Neonatal
bradycardia and hypoglycemia were not observed.
A feature of this trial is the unusually poor outcome
of the methyl-dopa-treated group given the selec-
tion criteria. It is possible that the benefit attributed
to oxprenolol represents inherent pretreatment dif-
ferences between the two groups despite adequate
randomization.
Adrenergic control of uterine activity is well es-
tablished. Beta-adrenergic blockade enhances uter-
ine activity in experimental animals, and in preg-
nant women in the second and third trimesters [135-
137]. Premature or precipitate labor might therefore
be a complication of treatment [123, 133], but the
larger series are reassuring on this point. Beta-
blockers cross the placenta with a speed dependent
on lipid-solubility, and both propranolol and ox-
prenolol have a long half-life in the fetal lamb [138].
Acute experiments in the ewe suggest that propran-
olol reduces umbilical blood flow [139] and impairs
the fetal lamb's ability to withstand acute anoxic
stress. If these data can be applied to the human
situation, then fetal problems might only be ex-
pected when there is already compromise in terms
of preexisting placental inadequacy.
Until more information is available, beta-adreno-
ceptor blocking agents should not be used routinely
in pregnancy.
Conclusions. (1) Extreme hypertension in preg-
nancy is as dangerous as it is in other medical situa-
tions and demands urgent treatment. (2) The treat-
ment of mild chronic hypertension in pregnancy
does not prevent the later superimposition of pre-
eclampsia. The perinatal advantages of such treat-
ment cannot be attributed to the hypotensive action
of the drugs. (3) Methyl dopa is the most thoroughly
tested hypotensive agent in pregnancy. Apart from
a possible effect on fetal head growth, if treatment is
started between 16 and 20 weeks' gestation, no sig-
nificant adverse reactions have been observed. (4)
Beta adrenoceptor antagonists may be safe to use in
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pregnancy but there are as yet inadequate trial data.
(5) Diuretics should be reserved for the treatment of
heart failure complicating preeclampsia.
Reprint request to Dr. C. W. G. Redman, Nuffield Department
of Obstetrics and Gynaecology, John Radcliffe Hospital, Ox-
ford, England
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